Taking advantage of mouse models of FMRP deficiency, employed in mechanistic and translational studies, we report here on an initial preclinical assessment of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, blarcamesine, half maximal inhibitory concentration, IC50 = 860 nM for the S1R34), a S1R agonist and muscarinic receptor modulator34 in FXS. This evidence concerns the gene FMR1 and fragile X syndrome.